{"id":"aroxybutynin-and-atomoxetine","safety":{"commonSideEffects":[{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Oxybutynin is an anticholinergic agent that relaxes bladder smooth muscle by antagonizing M3 muscarinic receptors, reducing urge incontinence. Atomoxetine is a selective norepinephrine reuptake inhibitor (NRI) that increases noradrenergic signaling in the central nervous system, potentially enhancing bladder control and attention. The combination targets both peripheral bladder dysfunction and central neurological components of incontinence.","oneSentence":"This combination drug blocks muscarinic acetylcholine receptors (via oxybutynin component) and inhibits norepinephrine reuptake (via atomoxetine component) to reduce urinary incontinence and improve attention.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:43:03.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with urge incontinence"},{"name":"Neurogenic detrusor overactivity (likely, given atomoxetine component)"}]},"trialDetails":[{"nctId":"NCT05811247","phase":"PHASE3","title":"Parallel Arm Trial of AD109 and Placebo With Patients With OSA (LunAIRo)","status":"COMPLETED","sponsor":"Apnimed","startDate":"2023-08-28","conditions":"OSA","enrollment":660},{"nctId":"NCT06566820","phase":"PHASE3","title":"Continuation Protocol for Obstructive Sleep Apnea (OSA)","status":"ENROLLING_BY_INVITATION","sponsor":"Apnimed","startDate":"2024-07-03","conditions":"OSA","enrollment":1280},{"nctId":"NCT06400615","phase":"PHASE2","title":"Study That Tests AD109 in Patients Taking GLP-1 Drugs","status":"COMPLETED","sponsor":"Apnimed","startDate":"2024-05-20","conditions":"OSA","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AD109"],"phase":"phase_3","status":"active","brandName":"Aroxybutynin and Atomoxetine","genericName":"Aroxybutynin and Atomoxetine","companyName":"Apnimed","companyId":"apnimed","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination drug blocks muscarinic acetylcholine receptors (via oxybutynin component) and inhibits norepinephrine reuptake (via atomoxetine component) to reduce urinary incontinence and improve attention. Used for Overactive bladder with urge incontinence, Neurogenic detrusor overactivity (likely, given atomoxetine component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}